Improvements were also seen in complete response rates, duration of response, and time to next treatment
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
FIBROSARC did not meet its primary PFS endpoint in the final analysi
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
